Customizing chemotherapy for colon cancer: the potential of gene expression profiling.
The value of gene expression profiling, or microarray analysis, for the classification and prognosis of multiple forms of cancer is now clearly established. For colon cancer, expression profiling can readily discriminate between normal and tumor tissue, and to some extent between tumors of different histopathological stage and prognosis. While a definitive in vivo study demonstrating the potential of this methodology for predicting response to chemotherapy is presently lacking, the ability of microarrays to distinguish other subtleties of colon cancer phenotype, as well as recent in vitro proof-of-principle experiments utilizing colon cancer cell lines, illustrate the potential of this methodology for predicting the probability of response to specific chemotherapeutic agents. This review discusses some of the recent advances in the use of microarray analysis for understanding and distinguishing colon cancer subtypes, and attempts to identify challenges that need to be overcome in order to achieve the goal of using gene expression profiling for customizing chemotherapy in colon cancer.
Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, 111, East 210th Street, Bronx, NY 10467, USA. jmariada@aeom.yu.edu
John M
JM
Mariadason
Diego
D
Arango
Leonard H
LH
Augenlicht
D003110:Colonic Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D005472:Fluorouracil / Q000494:pharmacology / Q000627:therapeutic use; D020869:Gene Expression Profiling; D006801:Humans; D011379:Prognosis
D005472:Fluorouracil